Physician profile
Salvatore Galluzzo
NPI 1831200104
$5,575.79
in general payments reported to CMS, 2019-2025
23 companies · $836 in 2025
The $836 reported for 2025 was more than what 77% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $319 · 2021: $805 · 2022: $720 · 2023: $523 · 2024: $599 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,900.81 | 2019-2023 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $826.18 | 2020-2025 | Nuzyra |
| Smith+Nephew, INC. | $335.74 | 2019-2022 | |
| Melinta Therapeutics, LLC | $321.43 | 2019 | |
| Tactile Systems Technology INC | $282.57 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Bioventus LLC | $274.74 | 2023-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Amgen INC. | $240.58 | 2024-2025 | Krystexxa |
| Organogenesis INC. | $224.87 | 2019-2021 | |
| Kerecis Limited | $181.33 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Next Science LLC | $138.99 | 2024 | Xperience, Blastx, Surgx |
| Advanced Oxygen Therapy INC. | $135.14 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $121.35 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.15 | 2019-2022 | |
| Crossroads Extremity Systems, LLC | $108.77 | 2019 | |
| Averitas Pharma INC. | $104.35 | 2023 | Qutenza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $100.00 | 2022 | |
| Alfasigma USA, INC. | $49.35 | 2021 | |
| Merck Sharp & Dohme LLC | $23.57 | 2019 | |
| Dynasplint Systems INC. | $20.86 | 2022 | |
| Grt US Holding, INC. | $20.80 | 2020 | |
| Cashflow Solutions, LLC | $19.72 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Vertex Pharmaceuticals Incorporated | $16.50 | 2025 | |
| Fidia Pharma USA INC. | $9.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Galluzzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.